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Background. Eradication of methicillin-resistant Staphylococcus aureus (MRSA) carriage may reduce the risk
of MRSA infection and prevent transmission of the organism to other patients.
Methods. To determine the efﬁcacy of decolonization therapy, patients colonized with MRSA were randomized
(3:1 allocation) to receive treatment (2% chlorhexidine gluconate washes and 2% mupirocin ointmentintranasally,
with oral rifampin and doxycycline for 7 days), or no treatment. Follow-up samples for MRSA culture were
obtained from the nares, perineum, skin lesions, and catheter exit sites monthly for up to 8 months. The primary
outcome measure was detection of MRSA at 3 months of follow-up. Univariate and multivariable analyses were
performed to identify variables associated with treatment failure.
Results. Of 146 patients enrolled in the study, 112 patients (87 treated; 25 not treated) were followed up for
at least 3 months. At 3 months of follow-up, 64 (74%) of those treated had culture results negative for MRSA,
compared with 8 (32%) of those not treated ( ). This difference remained signiﬁcant at 8 months of P p .0001
follow-up, at which time, 54% of those treated had culture results negative for MRSA ( ; , by
2 x p 64.4 P ! .0001
log-rank test). The results of the multivariable analysis indicated that having a mupirocin-resistantisolateatbaseline
was associated with treatment failure (relative risk, 9.4; 95% conﬁdence interval, 2.8–31.9; ), whereas P p .0003
decolonization therapy was protective (relative risk, 0.1; 95% conﬁdence interval, 0.04–0.4; ). Mupirocin P p .0002
resistance emerged in only 5% of follow-up isolates.
Conclusions. Treatmentwith topicalmupirocin,chlorhexidinegluconatewashes,oralrifampin,anddoxycycline
for 7 days was safe and effective in eradicating MRSA colonization in hospitalized patients for at least 3 months.
Staphylococcus aureus remains one of the most impor-
tant human bacterial pathogens. Infections due to
methicillin-resistant S. aureus (MRSA) have been as-
sociated with excess morbidity and mortality and with
increased costs [1–3].Transmissionofalimitednumber
of clones appears to be responsible for most commu-
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nity-associated and health care–associated MRSA dis-
ease [4]. Colonization with MRSA generally precedes
the development of MRSA infection and plays a major
role in the dissemination of this organism in health
care facilities [5].
Decolonization, primarily with topical mupirocin,
has been successful in reducing the risk of S. aureus
infection in select patient populations [6, 7], but in
other studies, this approach has not been effective [6,
8, 9]. In health care facilities, MRSA decolonizationhas
also been used, along with other interventions, as an
outbreak-management strategy [10, 11]. However, the
role of decolonization as an infection-control interven-
tion remains controversial, largely because no anti-
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microbial agents have been found to be effective in long-term
eradication of MRSA carriage in hospitalized patients [12–16].
Indeed, a recent Cochrane Collaboration review concludedthat
“there is insufﬁcient evidence to support use of topical or sys-
temic antimicrobial therapy for eradicating MRSA” [17, p. 8].
The present study was designed to determine the efﬁcacy of
therapy using a combination of topical and systemic antimi-
crobial agents (chlorhexidine gluconate washes and intranasal
mupirocin plus oral rifampin and doxycycline) for eradication
of MRSA colonization. We were also interested in identifying
variables that would predict success or failure of decolonization
therapy.
PATIENTS AND METHODS
Study population and setting. Patients hospitalized in any of
8 hospitals (6 acute-care hospitals, 1 rehabilitationhospital,and
1 chronic-care hospital) in Toronto or Hamilton, Ontario, be-
tween 1 July 2000 and 30 June 2003 who were colonized with
MRSA were eligible for inclusion in this study, provided that
they were 118 years of age and were expected to survive for
3 months. Patients were considered to be colonized with
MRSA if the organism was recovered by culture of samples
from 1 body site obtained at 2 separate times within 2 weeks
and if there was no evidence of infection on the basis of stan-
dard criteria [18]. Potentially eligible patients were identiﬁed
by MRSA screening done at each hospital at admission or as
part of outbreak investigation. Eligible patients who consented
to participate in the study had pretreatment (baseline) samples
for screening cultures obtainedfromtheanteriornares,perianal
area, any skin lesions, and catheter ormedicaldeviceexitsite(s).
Exclusion criteria were concurrent treatment with antimi-
crobials for an infection; an MRSA decolonization attempt in
the previous 6 months (prior treatment for an MRSA infection
was not an exclusion criterion); allergy to any of the study
medications; known antimicrobial resistanceto anyofthestudy
medications before randomization (if the isolate was subse-
quently found to be drug resistant after completion of treat-
ment, the patient was not excluded); inability to take medi-
cations by mouth or by enteral feeding tube; pregnancy or
breast-feeding; the presence of known hepatic cirrhosis or liver
function test abnormalities(abnormalinternationalnormalized
ratio or serum aspartate aminotransferase or alanine amino-
transferase levels 15 times the upper limit of normal); or
planned surgery in the following 3 months. The study was
approved by the Institutional Review Board at each partici-
pating hospital and by the University of Toronto.
Study design. This was an open-label, randomized study
comparing decolonization treatment with no treatment. Pa-
tients were randomized to treatment or no treatment in blocks
of 8 stratiﬁed by hospital in a 3:1 ratio. Patients randomly
assigned to treatment received a 7-day course of daily washes
with 2% chlorhexidine gluconate, 2% mupirocin ointment (∼1
cm) applied to the anterior nares with a cotton-tipped appli-
cator 3 times daily, rifampin (300 mg twice daily), and doxy-
cycline (100 mg twice daily). Treatment was started within 4
days of a culture result indicating the presence of MRSA. Com-
pliance with study medications and the occurrence of adverse
reactions were monitored.
Baseline demographic and clinical information was obtained
by patient interview and review of the medical records. The
presence of medical comorbidities was determined by docu-
mentation in the medical records or by a physician diagnosis.
Baseline functional status was assessed using the Katz index of
activities of daily living [19], a validated measure of function
in the chronically ill.
Follow-up cultures for MRSA were obtained from the an-
terior nares, perianal area, skin lesions, catheter or other med-
ical device exit site(s), and any other site that had previously
yielded MRSA. They were obtained weekly for 4 weeks after
randomization and then monthly for an additional 7 months.
Clinical data were obtained to identify the development of
MRSA infection for up to 8 months of follow-up.
Laboratory methods. Specimens for MRSA culture were
processed within 8 h of procurement. To optimize the recovery
of MRSA, the swabs were incubated overnight in a tryptone-
based broth containing 7.5% sodium chlorideand1%mannitol
(Difco m Staphylococcus broth; Becton Dickinson) and then
subcultured onto mannitol-salt agar supplemented with oxa-
cillin (2 mg/mL; Quelab) and incubated at 37 C for up to 48
h [20]. MRSA was identiﬁed using standardmethods,including
a latex agglutination test for detection of penicillin-binding
protein 2a (MRSA-Screen; Denka Seiken). Specimenswerepro-
cessed by laboratory staff who were blinded to the study pur-
pose and treatment allocation.
In vitro susceptibilities to mupirocin, rifampin, and tetra-
cycline were determined by broth microdilution, in accordance
with Clinical and Laboratory Standards Institute guidelines
[21]. High-level resistance to mupirocin was deﬁned as an MIC
of 512 mg/mL; low-level mupirocin resistance was deﬁned as
an MIC of 8–256 mg/mL [22]. To determine whether a second
isolate from a patient represented relapse with the same strain
or acquisition of a new strain, isolates were typed by PFGE
using SmaI digests of genomic DNA [23, 24].
Statistical analysis. Descriptive statistics were calculated
for baseline demographicandclinicalvariables.Univariateanal-
ysis was done using 2-sided Student’s t tests, x
2, and Fisher’s
exact tests as appropriate.
The primary outcome was eradication of MRSA from all
sites 3 months after completion of therapy in the treatment
group and 3 months after randomization in those not treated.
Secondary outcomes included survival analysis to compare the
probabilities of remaining free of MRSA colonization in all
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Figure 1. Disposition of patients colonized with methicillin-resistant
Staphylococcus aureus (MRSA) in a study of decolonization treatment.
evaluable study subjects; a separate survival analysis was done
excluding those subjects who acquired a new strain of MRSA
during follow-up, as determined by PFGE. Log-rank tests were
used to assess the signiﬁcance of treatment allocation.
Multivariable logistic regression analysis was performed to
assess the relationship of predictor variables of interest to treat-
ment failure at the primary end point of 3 months. The var-
iables included those identiﬁed in the univariate analysis as
possibly being associated with treatment failure ( ) and P ! .10
other variables that had been implicated in previous studies or
were biologically plausible. Before analysis, predictor variables
were assessed for the presence of collinearity.
All analyses were carried out using SAS software, version 9.1
(SAS Institute). All statistical tests were 2-tailed, with P ! .05
considered to be statistically signiﬁcant.
Sample size calculation. We assumed a priori that 20% of
untreated subjects would have culture results negative for
MRSA after 3 months of follow-up [16] and that 20% of sub-
jects would be lost to follow-up by 3 months. To detect a 30%
difference in MRSA decolonization rates ( ; ), a a p .05 b p .20
sample size of 78 evaluable patients (100 enrolled) in the treat-
ment group and 26 evaluable patients (33 enrolled) in the no-
treatment group would be required.
RESULTS
A total of 146 eligible consenting patients were recruited for
the study; 111 were randomized to receive decolonizationther-
apy, and 35 were randomized to receive no treatment. Thirty-
four patients (23%) were not evaluable at 3 months, leaving
112 patients for the analysis of primary outcome (87 in the
treatment group and 25 in the no-treatment group) (ﬁgure 1).
Baseline demographic and clinical characteristics were similar
between groups (table 1). There were also no signiﬁcant dif-
ferences in these characteristics for those subjects not com-
pleting 3 months of follow-up, compared with those subjects
who did complete 3 months of follow-up (data not shown).
At 3 months following treatment (or randomization, for
those not treated), 64 patients (74%) in the treatment group
had all results of follow-up cultures negative for MRSA, com-
pared with only 8 patients (32%) in the no-treatment group
(relative risk [RR], 1.55; 95% CI, 1.17–2.04; ). Sur- P p .0003
vival analysis (ﬁgure 2A) demonstrated a signiﬁcant difference
in the recovery of MRSA from treated patients, compared with
patients who were not treated, over time ( ; P!.0001,
2 x p 64.4
by log-rank test).
A total of 110 (98%) of the initial MRSA isolates obtained
at baseline (86 from treated patients and 24 from untreated
patients) were available for antimicrobial susceptibility testing
and genotyping by PFGE. Twenty-one (19%) of these MRSA
isolates were subsequently found to have high-level resistance
to mupirocin. Only 5 baseline isolates (5%) had low-level mu-
pirocin resistance.
The most commonly identiﬁed MRSA strains were CMRSA-
2 (46%; identical to or closely resembling USA100 ST5) and
CMRSA-1 (24%; USA600 ST45). This genotype distribution
was representative of that seen in hospitalized patientsinsouth-
ern Ontario [23]. Only 1 isolate was identiﬁed as CMRSA-7
(USA400 ST1), and none had the USA300 proﬁle. There was
no difference in the genotype distribution of the isolates ob-
tained at baseline between subjects randomized to treatment
and subjects randomized to no treatment. Most (82%) of the
72 patients with MRSA recovered in follow-up cultures had
follow-up strains that were identical to their baseline isolates,
as determined by PFGE typing. Thirteen patients (18%) had
initial and follow-up isolates that represented different strains
by PFGE typing (9 patients in the treatment group and 4 pa-
tients not receivingdecolonizationtherapy).Becausethesecases
represented acquisition of a new strain of MRSA, rather than
failure to eradicate the initial colonizing strain, Kaplan-Meier
survival curves were created excluding these 13 patients (ﬁgure
2B). This analysis also demonstrated a signiﬁcant difference in
rates of recovery of MRSA over time in treated patients, com-
pared with untreated patients ( ; , by log-
2 x p 50.1 P ! .0001
rank test).
Three (5%) of 61 treated study participants with baseline
MRSA isolates that were susceptible to mupirocin had follow-
up cultures that yielded MRSA with high-level resistance to
mupirocin. In 2 of these patients, the genotypes of the initial
and follow-up isolates, as determined by PFGE, were distinct,
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Table 1. Demographic and clinical characteristics at baseline of study patients
who completed 3 months of follow-up.
Characteristic
Randomized to
treatment
a
(n p 87)
Randomized to
no treatment
b
(n p 25) P
Age, mean years   SD 77.3   11.6 76.2   12.2 .68
Female sex 32 (37) 8 (32) .66
Katz index of activities of daily living score
A 7 (8) 3 (12) .29
B 16 (18) 7 (28)
C 10 (11) 6 (24)
D 6 (7) 2 (8)
E 11 (13) 1 (4)
F 11 (13) 3 (12)
G 26 (30) 3 (12)
Dementia 26 (30) 11 (44) .19
Stroke 28 (32) 5 (20) .23
Chronic lung disease 25 (29) 9 (36) .49
Cardiac disease 29 (33) 12 (48) .19
Diabetes mellitus 23 (26) 5 (20) .51
Immunosuppression 7 (8) 3 (12) .69
Skin lesions 33 (38) 7 (28) .36
Hospitalized in previous 6 months 46 (53) 13 (52) .90
Nursing home in previous 6 months 17 (20) 6 (24) .65
Surgery in previous 30 days 11 (13) 3 (12) .99
Antibiotic treatment in previous 30 days 40 (46) 13 (52) .63
Previously treated for MRSA infection 1 (1) 0 (0) 1.00
Urinary catheter 19 (22) 8 (32) .30
Intravascular catheter 24 (28) 7 (28) .97
Tracheostomy 5 (6) 2 (8) .68
Percutaneous enteral feeding tube 21 (24) 2 (8) .08
MRSA recovered from 11 body site 56 (64) 18 (72) .48
MRSA resistant to mupirocin at baseline 16 (18) 5 (20) .98
MRSA resistant to rifampin at baseline 3 (3) 0 (0) .99
MRSA resistant to tetracycline at baseline 1 (1) 0 (0) 1.00
NOTE. Data are no. (%) of patients with the speciﬁed characteristic, unless otherwise indicated.
MRSA, methicillin-resistant Staphylococcus aureus.
a A total of 111 patients were randomized to receive treatment; of these, 87 completed3months
of follow-up.
b A total of 35 patients were randomized to receive no treatment; of these, 25 completed 3
months of follow-up.
suggesting acquisition of a new strain of MRSA. In the third
patient, the initial and follow-up isolates had indistinguishable
PFGE proﬁles. One of the follow-up mupirocin-resistant iso-
lates in a treated patient was also resistant to tetracycline; this
isolate had a PFGE genotype different from that of the initial
MRSA strain recovered from this patient. None of the follow-
up isolates developed resistance to rifampin.
In univariate analysis, patients who remained colonized with
MRSA at 3 months aftertreatmentorrandomizationweremore
likely to have had a mupirocin-resistant isolateat baseline(40%
vs. 7%; RR, 2.89; 95% CI, 1.90–4.39; ) and were less P p .0002
likely to have been randomized to receive decolonization ther-
apy (58% vs. 89%; RR, 0.26; 95% CI, 0.12–0.55; ) P p .0001
(table 2). In the multivariable analysis, having a mupirocin-
resistant isolate at baseline (RR, 9.37; 95% CI, 2.76–31.9;
) remained independently associated with recovery P p .0003
of MRSA in culture by 3 months of follow-up. Receipt of
decolonization therapy was protective, associated with negative
results of culture for MRSA at 3 months of follow-up (RR,
0.12; 95% CI, 0.04–0.36; ) (table 3). P p .0002
Compliance with decolonization therapy was good, with 102
patients (92%) completing at least 6 days of treatment and the
remaining 9 subjects completing 2–5 days oftreatment.Adverse
reactions possibly related to medications were reported in 22
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Figure 2. A, Kaplan-Meier curve demonstrating the probability of re-
maining culture-negative for methicillin-resistant Staphylococcus aureus
(MRSA) over time in patients receiving decolonization therapy (2% chlor-
hexidine soap, 2% mupirocin ointment,plusoralrifampinanddoxycycline),
compared with patients randomized to receive no treatment. Thisanalysis
includes all randomized patients with follow-up of 3 months (
2 x p
; , by log-rank test). B, Kaplan-Meier curve demonstrating 64.4 P ! .0001
the probability of remaining culture negative for MRSA over time in
patients receiving decolonization therapy (2% chlorhexidine soap, 2%
mupirocin ointment, oral rifampin and doxycycline), compared with pa-
tients randomized to receive no treatment. This analysis excludes 13
patients with follow-up MRSA isolates distinct from their initial baseline
isolates, as determined by pulsed-ﬁeld gel electrophoresis typing (x
2
p50.1; , by log-rank test). P ! .0001
(25%) of the treated patients. All of these reactions were con-
sidered to be mild and included nausea or vomiting (15 pa-
tients), diarrhea (9 patients), and dyspepsia (5 patients). An-
timicrobial therapywasdiscontinuedin4patients(5%)because
of adverse effects. Thirty-one study participants died during
the study: 25 (23%) of the patients randomized to receive de-
colonization therapy and 6 (17%) of the patients randomized
to no treatment ( ). None of the patients developed an P p .64
MRSA infection during the study.
DISCUSSION
Eradication of MRSA carriage may reduce the risk of subse-
quent MRSA infection in individual patientsandcoulddecrease
MRSA transmission by eliminatingareservoirfortheorganism.
Indeed, recommendations to consider decolonization of hos-
pitalized patients with nasal carriage of MRSA have been made
[25]. Colonization with S. aureus or MRSA in health carework-
ers, who are generally healthy young adults, may be successfully
eradicatedwith ashortcourseofintranasalmupirocinointment
[26]. Up to now, however, attempts to eradicate MRSA colo-
nization in hospitalized patients have had little success [27].
Although short-term MRSA decolonization has been accom-
plished in several observational and uncontrolled studies [10,
12, 28, 29], only 1 randomized controlled trial has demon-
strated efﬁcacy for eradication of MRSA carriage for up to 90
days [30]. Previous studies have generally been underpowered,
have had short-term (!1 month) follow-up, or have failed to
show efﬁcacy [13–17, 31–33]. The results of this study, using
a combination of topicaland oralsystemicantimicrobialagents,
indicate that MRSA decolonization may be achieved for pro-
longed periods of time and that such treatment is generally
well tolerated without signiﬁcant adverse effects. At the end of
decolonization treatment for 7 days, 92% of patients cleared
MRSA from all sites, and 74% remained free of MRSA at 3
months of follow-up. Eight months after treatment, more than
one-half (54%) of those available for follow-up still had neg-
ative results of culture for MRSA. Emergence of mupirocin
resistance occurred infrequently.
Colonization with MRSA in hospitalized patients is not nec-
essarily benign. In a study of patients in an intensive care unit,
the risk of developing MRSA bacteremia in patients colonized
with MRSA was higher than the risk of developing staphylo-
coccal bacteremia in patients colonized with susceptible strains
of S. aureus [34]. Huang et al. [35] found that 29% of 209
hospitalized patients newly identiﬁed as having MRSA colo-
nization developed a subsequent MRSA infection in up to 18
months of follow-up; these infections occurred a mean of 102
days after the initial MRSA culture result. Even without infec-
tion, implementation of isolation precautions to limit trans-
mission of MRSA may be associated with diminished quality
of care and decreased patient safety [36]. These adverse con-
sequences associated with MRSA colonization suggestthateven
partially effective decolonization, such as that achieved in this
study, could be useful in reducing the burden of disease caused
by MRSA.
Possible explanations for failure to eradicate MRSA colo-
nization in previous studies may include the use of agents with
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Table 2. Comparison of demographic and clinical characteristics of patients with and patients with-
out methicillin-resistant Staphylococcus aureus (MRSA) colonization at 3 months of follow-up.
Variable
MRSA
isolated at
3 months
(n p 40)
MRSA
not isolated at
3 months
(n p 72)
Relative risk
(95% CI) P
Age, mean years   SD 76.9   11.3 77.1   11.9 .93
Female sex 17 (43) 23 (32) 1.18 (0.87–1.61) .26
Katz index of activities of daily living
score A or B 30 (75) 40 (56) 1.24 (0.65–2.35) .50
Dementia 12 (30) 25 (35) 0.93 (0.72–1.21) .61
Stroke 13 (33) 20 (28) 1.06 (0.81–1.39) .67
Chronic lung disease 14 (35) 20 (28) 1.11 (0.85–1.45) .43
Cardiac disease 13 (33) 28 (39) 0.92 (0.69–1.22) .56
Renal disease 10 (25) 16 (22) 1.04 (0.83–1.29) .74
Diabetes mellitus 10 (25) 18 (11) 1.00 (0.80–1.25) 1.00
Immunosuppression 2 (5) 8 (20) 0.94 (0.84–1.04) .49
Skin lesions 13 (33) 27 (38) 0.93 (0.70–1.22) .60
Hospitalized in previous 6 months 24 (60) 35 (49) 1.34 (0.85–2.11) .19
Nursing home in previous 6 months 6 (15) 17 (24) 0.90 (0.75–1.09) .31
Surgery in previous 30 days 5 (13) 9 (13) 1.01 (0.87–1.61) 1.00
Antibiotic treatment in previous 30 days 20 (50) 33 (46) 1.11 (0.76–1.64) .58
Previously treated for MRSA infection 0 (0) 1 (1) 0.99 (0.96–1.01) 1.00
Urinary catheter 11 (28) 16 (22) 1.07 (0.85–1.35) .53
Intravascular catheter 9 (23) 12 (17) 1.11 (0.83–1.32) .36
Tracheostomy 3 (8) 4 (6) 1.02 (0.92–1.13) .68
Percutaneous enteral feeding tube 11 (28) 12 (17) 1.15 (0.93–1.43) .17
Any medical device 22 (55) 40 (56) 0.99 (0.64–1.52) .95
MRSA recovered from 11 body site 29 (73) 45 (63) 1.36 (0.76–2.45) .28
MRSA resistant to mupirocin at baseline 16 (40) 5 (7) 2.89 (1.90–4.39) .0002
MRSA resistant to rifampin at baseline 2 (5) 1 (1) 1.91 (0.83–4.43) .29
MRSA resistant to tetracycline at baseline 0 (0) 1 (1) 0.99 (0.97–1.01) 1.00
Randomized to decolonization therapy 23 (58) 64 (89) 0.26 (0.12–0.55) .0001
NOTE. Data are no. (%) of patients, unless otherwise indicated.
only marginal in vitro activity against the organism or the use
of agents (such as ciproﬂoxacin and fusidic acid) that induce
the development of resistance during therapy [31, 32]. Alter-
natively, decolonization may, in fact, succeed, but the patient
is re-exposed to the organism and becomes colonized with a
new strain of MRSA. This likely occurred in 13 (18%) of the
patients in the current study. In several previous studies,failure
to eradicate MRSA carriage has been associated with multiple
extranasal sites of colonization [15, 37]. The gastrointestinal
tract is recognized as a potentially important reservoir for the
organism [38], and intranasal treatment alone is unlikely to
eradicate intestinal carriage. In the current study, the presence
of MRSA at multiple bodysiteswasnotassociatedwithrecovery
of MRSA in follow-up cultures, possibly because topical treat-
ment was combined with effective oral systemic drugs. Simi-
larly, impaired functional status (as measured by the Katz index
of activities of daily living [19]), and the presence of medical
devices or skin lesions (such as decubitus ulcers) were not
associated with recolonization or persistence of MRSA, despite
the association of these variables with MRSA colonization in
health care facilities [29, 39]. However, it is important to note
that the power of this study to identify risk factors was limited.
Because previous studies have reported failure of MRSA de-
colonization in association with mupirocin resistance [16, 40],
patients known to have a mupirocin-resistant isolate before
randomization were excluded from our study. However, the
results of mupirocin susceptibility testing were notalwaysavail-
able before randomization, so 21 patients colonizedwithMRSA
with high-level mupirocin resistance were enrolled in the study.
As previously reported [40], colonization with MRSA with
high-level mupirocin resistance was associated with failure of
decolonization therapy. The signiﬁcance of low-level resistance
could not be assessed, because only 5 study subjects hadisolates
with low-level resistance. Although we observed a relativelylow
rate of mupirocin resistance developing in follow-up MRSA
isolates from study subjects, the potential for the emergence of
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Table 3. Results of multivariable logistic regression analysis to determine
variables independently associated with recolonization with methicillin-
resistant Staphylococcus aureus (MRSA) within 3 months of follow-up.
Variable
Relative risk
(95% CI) P
Katz index of activities of daily living score
a 0.45 (0.16–1.31) .14
Presence of skin lesions 0.71 (0.27–1.87) .48
Presence of a medical device
b 1.56 (0.62–3.94) .35
MRSA recovered from 11 body site 1.39 (0.53–3.70) .50
Mupirocin-resistant MRSA at baseline 9.37 (2.76–31.87) .0003
Randomized to received decolonization therapy
c 0.12 (0.04–0.36) .0002
a Katz index of activities of daily living score of A or B vs. index score C, D, E, F , or G.
b For example, intravascular catheter, urinary catheter, tracheostomy, or percutaneous
enteral feeding tube.
c Decolonization therapy consisting of treatment for 7 days with chlorhexidine soap,
intranasal mupirocin ointment, oral rifampin, and oral doxycycline.
such resistance occurring with widespread use of mupirocin is
of concern, and even limited development of resistance em-
phasizes the importance of using this agent judiciously [41].
Strengths of the current study include its study design, rel-
atively long follow-up period, and inclusion of a sample size
adequate for determination of treatment efﬁcacy and for as-
sessment of variables associated with treatment failure. The use
of a broth culture enhanced sensitivity for the laboratory de-
tection of MRSA, and the study was also able to examine the
risk of emergence of mupirocin resistance in MRSA isolates
recovered from study participants. Molecular typing by PFGE
enabled us to distinguish relapse from acquisition of a new
strain of MRSA in follow-up cultures.
This study also has limitations. Althoughitwasarandomized
trial, the study was not placebo-controlled and was not a dou-
ble-blind study. However, this should not have affected the
outcome measurement, because MRSA persistence or recolon-
ization after 3 months of follow-up was determined by culture,
without knowledge of allocation to receive treatment or to not
receive treatment. As anticipated, there were patients lost to
follow-up. Although those lost to follow-up appeared to be
similar to those who were evaluablewithregardtodemographic
and clinical characteristics, it is possible that some unmeasured
differences were important. The study included only hospital-
ized patients with MRSA, and the results may not be gener-
alizable to other patient populations, such as residents of nurs-
ing homes, or to those with community-associated MRSA.
In summary, the results of this study indicate that hospital-
ized patients colonized with MRSA may be successfully decol-
onized with a 7-day course of chlorhexidine gluconate washes,
intranasal 2% mupirocin ointment, and oral rifampin anddox-
ycycline. With this treatment, approximately three-quarters of
patients are likely to remain decolonized for at least 3 months,
and more than one-half will still have cultures negative for
MRSA up to 8 months later. The study reafﬁrms the clinical
signiﬁcance of high-level mupirocin resistanceandsuggeststhat
susceptibility testing should be done in advance if treatment
with mupirocin is being considered. Because MRSA decolo-
nization has now been demonstrated to be feasible in a sub-
stantial proportion of hospitalized patients, the role of decol-
onization therapy as an infection control strategy deserves
serious consideration and evaluation.
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